A powder injection of a proton pump inhibitor

By preparing a powder injection of compound (I), the problems of unstable efficacy and applicability of existing proton pump inhibitors and enteric-coated tablets are solved, providing a highly stable and easily soluble proton pump inhibitor injection suitable for the treatment of gastric acid-related diseases such as severe peptic ulcers.

CN121370789BActive Publication Date: 2026-05-05XUANZHU (BEIJING) BIOPHARMACEUTICAL LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202511983584.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-12-26
Publication Date
2026-05-05
Estimated Expiration
2045-12-26

AI Technical Summary

Technical Problem

Existing proton pump inhibitors, such as omeprazole, have limitations such as large individual differences in efficacy, acid-suppressing effect affected by administration time and food, and slow onset of action. Furthermore, enteric-coated tablets are not suitable for critically ill patients who cannot take oral medication.

Method used

A powder injection of a compound of formula (I) is provided, comprising an active ingredient and an excipient in a mass ratio of 1:1 to 1:10, and a chelating agent such as sodium edetate, prepared by a freeze-drying process, with the pH value adjusted to 10.5 to 12.0 to ensure stability and bioactivity.

Benefits of technology

The powder injection avoids the stability problems caused by high-temperature sterilization. After freeze-drying, it is porous and easy to dissolve, making it suitable for critically ill patients who cannot take oral medication. It significantly inhibits gastric ulcers and improves the treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121370789B_ABST
    Figure CN121370789B_ABST
Patent Text Reader

Abstract

This invention provides a lyophilized powder injection of a proton pump inhibitor and its use therein, the lyophilized powder injection comprising a compound of formula (I) and an excipient. The powder injection provided by this invention is stable in properties, has controllable quality, and its preparation process is highly reproducible, meeting the needs of commercial production. Formula (I).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the pharmaceutical field, specifically relating to an injectable proton pump inhibitor, and more specifically, to a lyophilized powder injection of a proton pump inhibitor and its uses. Background Technology

[0002] Digestive system diseases are among the most common and frequently occurring illnesses, with peptic ulcers affecting approximately 10% to 12% of the total population. Gastric acid is the primary cause of peptic ulcers. Initially, treatment primarily involved using antacids (such as sodium bicarbonate and aluminum hydroxide) to neutralize gastric acid and alleviate symptoms. However, since the 1970s, the discovery of H2 receptor antagonists and proton pump inhibitors (PPIs) has opened up entirely new avenues for treating peptic ulcers. These drugs work by interacting with H2 receptor antagonists on secretory microtubules formed by the apical membrane of parietal cells and tubular vesicles within the cytoplasm. + K + -ATPase, causing irreversible inhibition of the enzyme, thereby effectively inhibiting gastric acid secretion, with the characteristics of rapid effect and high ulcer healing rate, greatly reducing the surgical operation rate.

[0003] First-generation proton pump inhibitors (OPIs) (omeprazole, lansoprazole, and pantoprazole) have good efficacy and tolerability, but due to significant individual variability in efficacy, the influence of administration time and food on acid-suppressing effect, insufficient duration of acid suppression, and slow onset of action, they are not ideal drugs for treating acid-related diseases. Second-generation PPIs (rabeprazole and esomeprazole) have largely overcome the limitations of first-generation PPIs. They have a rapid onset of acid suppression, maintain high acid-suppressing levels throughout the day, provide stable acid suppression in a wide range of patient populations, and have no significant drug interactions.

[0004] Compound (I) is a novel proton pump inhibitor with advantages such as a longer half-life, moderate acid suppression, high safety, and low risk of drug interactions. It can be used clinically to treat gastric acid-related diseases such as peptic ulcers and gastroesophageal reflux disease. The chemical structure of compound (I) is shown below.

[0005] Formula (I)

[0006] Patent applications CN102712649A and CN114224861A also provide enteric-coated tablets of the compound of formula (I), but these tablets are only suitable for treating peptic ulcers caused by benign ulcerative damage to the gastric and duodenal mucosa due to the action of gastric acid and pepsin. For critically ill patients who cannot take oral medication, such as those with peptic ulcer bleeding, acute gastric mucosal lesions with bleeding under stress ulcers, severe stress response to acute gastric mucosal damage, and those who need to prevent upper gastrointestinal bleeding caused by severe illness and gastric surgery, it is necessary to develop an injectable formulation. Summary of the Invention

[0007] The object of this invention is to provide a powder injection of a compound of formula (I). Furthermore, this invention also provides a method for preparing the powder injection of compound (I). Additionally, this invention provides uses for the powder injection of compound (I).

[0008] The technical solution of the present invention is as follows:

[0009] This invention provides a powder injection of a compound of formula (I), comprising the active ingredient of formula (I) and an excipient, wherein the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:10. In some embodiments, the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:8. In some embodiments, the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:6. In some embodiments, the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:5. In some embodiments, the mass ratio of the compound of formula (I) to the excipient is 1:2 to 1:4. In some embodiments, the mass ratio of the compound of formula (I) to the excipient is 1:3 to 1:4.

[0010] In some embodiments, the excipient is selected from one or more of mannitol, xylitol, glucose, sucrose, trehalose, or sulfadiazine-β-cyclodextrin. In some embodiments, the excipient is selected from one or both of mannitol and sulfadiazine-β-cyclodextrin. In some embodiments, the excipient is mannitol.

[0011] In some embodiments, the powder injection of the compound of formula (I) further includes a chelating agent. In some embodiments, the chelating agent is selected from one or more of disodium edetate, calcium sodium edetate, sodium citrate, or sodium tartrate. In some embodiments, the chelating agent is calcium sodium edetate.

[0012] In some embodiments, the weight-to-volume ratio (W / V) of the chelating agent, calculated as the ratio of the mass of the chelating agent to the volume of the drug solution, is 0.01% to 1%. In some embodiments, the weight-to-volume ratio (W / V) of the chelating agent is 0.01% to 0.5%. In some embodiments, the weight-to-volume ratio (W / V) of the chelating agent is 0.02% to 0.2%. In some embodiments, the weight-to-volume ratio (W / V) of the chelating agent is 0.02% to 0.1%. In some embodiments, the weight-to-volume ratio (W / V) of the chelating agent is 0.05% to 0.1%.

[0013] In some embodiments, each vial of powder for injection contains compound (I) in an amount of 20 mg to 60 mg.

[0014] In some embodiments, each vial of powder for injection contains compound (I) in amounts of 20 mg, 30 mg, 40 mg, 50 mg, or 60 mg.

[0015] In some embodiments, each vial of powder for injection contains 20 mg of compound (I) and 20 mg to 200 mg of excipient.

[0016] In some embodiments, each vial of powder for injection contains the compound of formula (I) in an amount of 20 mg, and the excipients in amounts of 20 mg, 40 mg, 60 mg, 62.5 mg, 80 mg, 100 mg, 125 mg, 140 mg, 160 mg or 180 mg.

[0017] In some embodiments, each vial of powder for injection contains 30 mg of compound (I) and 30 mg to 300 mg of excipient.

[0018] In some embodiments, each vial of powder for injection contains the compound of formula (I) in an amount of 30 mg, and the excipients in amounts of 30 mg, 60 mg, 90 mg, 93.75 mg, 120 mg, 150 mg, 180 mg, 210 mg, 240 mg, or 270 mg.

[0019] In some embodiments, each vial of powder for injection contains 40 mg of compound (I) and 40 mg to 400 mg of excipient.

[0020] In some embodiments, each vial of powder for injection contains the compound of formula (I) in an amount of 40 mg, and the excipients in an amount of 40 mg, 80 mg, 120 mg, 125 mg, 160 mg, 200 mg, 240 mg, 280 mg or 360 mg.

[0021] In some embodiments, each vial of powder for injection contains 40 mg of compound (I) and 125 mg of excipient.

[0022] In some implementations, the chelating agent is present in each vial of powder for injection at an amount of 0 to 10 mg.

[0023] In some implementations, the chelating agent is present in each vial of powder for injection at an amount of 0 to 5 mg.

[0024] In some implementations, the chelating agent is present in each vial of powder for injection at an amount of 0 to 3 mg.

[0025] In some embodiments, the pH of the solution before filling the lyophilized powder injection is 10.5 to 12.0; preferably 11.0 to 12.0.

[0026] In another aspect, the present invention also provides a method for preparing a powder injection of the compound of formula (I) above. The preparation method is as follows:

[0027] 1) Dissolve the excipients;

[0028] 2) Add the compound of formula (I) to the solution in step 1) to dissolve, and adjust the pH of the solution to 10.5 ~ 12.0 with an inorganic base; 3) Filter and freeze dry.

[0029] In some embodiments, the preparation method of the above-mentioned formula (I) compound powder injection provided by the present invention is as follows:

[0030] 1) Dissolve the excipient in water for injection;

[0031] 2) Add the compound of formula (I) to the solution in step 1) to dissolve, and adjust the pH of the solution to 10.5~12.0 with an inorganic base; 3) Filter, dispense, freeze dry, stopper and cap to obtain powder injection.

[0032] In some embodiments, the method for preparing the powder injection of the compound of formula (I) is wherein the pH value is 11.0 to 12.0.

[0033] In some embodiments, the inorganic base in the preparation method of the compound powder injection of formula (I) is selected from one or more of sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, and disodium hydrogen phosphate; preferably, the inorganic base is sodium hydroxide.

[0034] In some embodiments, a powder injection of a compound of formula (I) comprises the active ingredient compound of formula (I) and an excipient, wherein the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:8; the excipient is selected from one or two of mannitol or sulfobutyl-β-cyclodextrin; optionally, the powder injection of the compound of formula (I) further comprises a chelating agent; the chelating agent is selected from one or more of disodium edetate, calcium sodium edetate, sodium citrate or sodium tartrate.

[0035] In some embodiments, a powder injection of a compound of formula (I) comprises the active ingredient compound of formula (I) and an excipient, wherein the mass ratio of the compound of formula (I) to the excipient is 1:1 to 1:8; the excipient is selected from one or both of mannitol or sulfadiazine-β-cyclodextrin; and is obtained by the following method:

[0036] 1) Dissolve the excipients;

[0037] 2) Add the compound of formula (I) to the solution in step 1) to dissolve, and adjust the pH of the solution to 10.5 ~ 12.0 with an inorganic base; 3) Filter and freeze dry.

[0038] In another aspect, the present invention also provides the use of the above-mentioned powder injection in the preparation of a medicament for treating peptic ulcer bleeding, acute gastric mucosal lesion bleeding caused by stress ulcers, severe stress response to acute gastric mucosal damage, and preventing upper gastrointestinal bleeding caused by serious illness and gastric surgery.

[0039] In some embodiments, the peptic ulcer bleeding includes, but is not limited to, gastric ulcer bleeding and duodenal ulcer bleeding.

[0040] On the other hand, the present invention also provides a method for treating diseases such as peptic ulcer bleeding, acute gastric mucosal lesion bleeding under stress ulcers, severe stress response to acute gastric mucosal damage, and prevention of serious diseases and upper gastrointestinal bleeding caused by gastric surgery, using the above-mentioned powder injection. This method includes administering a therapeutically effective amount of the powder injection to a patient requiring this treatment. The powder injection can be administered in any conventional and acceptable manner known in the art. The therapeutically effective amount is adjusted according to the patient's region, sex, age, weight, medical conditions, type of disease, severity of disease, route of administration, relevant health conditions, and other factors known to those skilled in the art.

[0041] In this invention, unless otherwise stated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art.

[0042] In this invention, "optionally" means that the event in the following description may or may not occur; for example, "optionally includes" means either "includes" or "does not include".

[0043] As used herein, a “therapeutic effective amount” means an amount sufficient to cure or at least partially stop the disease and its complications in a patient who already has the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient’s own immune system, the patient’s general characteristics such as age, weight, and sex, the manner of administration of the drug, and any other concurrent treatments, etc.

[0044] Any one or any combination of two or more of the above solutions described in this invention are included within the protection scope of this invention.

[0045] The powder injection provided by this invention has the following advantages:

[0046] 1) It avoids stability issues that may be caused by products that are not tolerant to high-temperature sterilization, thus improving product stability.

[0047] 2) Freeze-dried powder injections are loose and porous, and can be quickly dissolved in water, making them convenient for clinical administration.

[0048] 3) It helps to preserve biological activity, allowing the drug to exert its therapeutic effect better after entering the human body. Detailed Implementation

[0049] The following detailed description of the present invention, in conjunction with specific embodiments, further illustrates the above-mentioned content. It should be understood that the following embodiments are for illustrative purposes only and are not intended to limit the scope of protection of this disclosure. Unless otherwise specified in the following embodiments, conditions are performed according to conventional conditions or manufacturer recommendations. Drugs or reagents used without a specified manufacturer are all commercially available conventional products.

[0050] The compounds of formula (I) used in the following examples were prepared according to the preparation method of Example 14 in the specification of patent application CN201180006795.1.

[0051] Example 1: Investigation of Excipient Types

[0052] 1. Prescription

[0053]

[0054] 2. Preparation

[0055] 1) Preparation of stock solution: First, dissolve the excipient in water for injection, then add the compound of formula (I) and dissolve it. Adjust the pH value with 1 mol / L sodium hydroxide. Filter through a 0.22 μm microporous membrane.

[0056] 2) Dispensing of the drug solution: Dispense the above drug solution into 7 ml vials, each with a volume of 2.5 ml.

[0057] 3) Freeze-drying: Place the vial into the freeze dryer and freeze-dry according to the freeze-drying program.

[0058] 4) Pressing and sealing.

[0059] 3. Stability test

[0060] Prescriptions 1-1, 1-2, 1-3, 1-4, 1-5, and 1-6 were placed in an environment of 60℃ for 10 days, and their properties were observed and related substances were tested.

[0061] 4. Experimental Results

[0062] Table 1. Stability results of different excipients

[0063]

[0064] Experimental conclusion:

[0065] As shown in Table 1, mannitol, sucrose, trehalose, and sulfanyl-β-cyclodextrin exhibit good stability when used as excipients; sorbitol shows poor stability when used as an excipient. When sucrose and trehalose are used as stabilizers, the color of compound (I) changes; therefore, mannitol and sulfanyl-β-cyclodextrin are preferred choices.

[0066] Example 2: Investigation of Excipient Dosage

[0067] 1. Prescription

[0068]

[0069] 2. Preparation

[0070] Prepared according to the method of Example 1, based on the prescription.

[0071] 3. Stability test

[0072] Prescriptions 2-1, 2-2, and 2-3 were placed in an environment of 60°C for 10 days, and their properties were observed and related substances were tested.

[0073] 4. Experimental Results

[0074] Table 2 Results of the study on excipient dosage

[0075]

[0076] Experimental conclusions

[0077] Different amounts of mannitol added affect its stability. Under the condition of 60℃ for 10 days, the related substances of prescription 2-3 increased significantly, while prescriptions 2-1 and 2-2 were relatively stable.

[0078] Example 3: Investigation of Chelating Agent Dosage

[0079] 1. Prescription

[0080]

[0081] 2. Preparation

[0082] Prepared according to the method of Example 1, based on the prescription.

[0083] 3. Stability test

[0084] Prescriptions 3-1, 3-2, 3-3, and 3-4 were placed in an environment of 40℃ and 75% RH for one month, and related substances were tested.

[0085] 4. Experimental Results

[0086] Table 3 Results of Chelating Agent Dosage Study

[0087]

[0088] Experimental conclusions

[0089] As can be seen from the results in Table 3, adding different amounts of calcium sodium edetate and not adding calcium sodium edetate had no impact on product quality.

[0090] Example 4. pH stability study of the lyophilized powder mother liquor

[0091] 1. Prescription

[0092]

[0093] 2. Preparation

[0094] According to the prescription, the mother liquor was prepared according to the method of Example 1 to obtain the mother liquor.

[0095] 3. Stability test

[0096] The mother liquors of prescriptions 4-1, 4-2, 4-3, 4-4, 4-5, 4-6, 4-7, and 4-8 were placed at room temperature, and the stability of related substances was investigated at 0h, 4h, 8h, and 24h. Related substances were then tested.

[0097] 4. Stability test results

[0098] Table 4. Stability assessment at different pH levels

[0099]

[0100] As shown in Table 4, when the pH of the powder injection mother liquor is 10.0, precipitation occurs after 1 hour of standing; the stability of the powder injection mother liquor is better when the pH is between 10.5 and 12.0.

[0101] Example 5. Stability study of freeze-dried powder

[0102] 1. Prescription

[0103] Prepare according to the prescription and preparation method in prescription 3-1.

[0104] 2. Stability test

[0105] Prescription 3-1 was placed at 60℃ for 10 days, at 25℃ for 6 months, and at 30℃ for 6 months, and related substances were tested.

[0106] Table 5. Stability test results

[0107]

[0108] Result evaluation:

[0109] As can be seen from the results in Table 5, Formula 3-1 showed good stability under the conditions of being placed at 60℃ for 10 days, at 25℃ for 6 months, and at 30℃ for 6 months.

[0110] Experimental Example 1. Effects of Intravenous Drug Administration on Rats with Pyloric Ligation-Induced Gastric Ulcers

[0111] 1. Test sample

[0112] Formula 3-1 was prepared according to the method of Example 1.

[0113] 2. Experimental Methods

[0114] Male Wistar rats were fasted for 48 hours but allowed free access to water. They were then anesthetized with isoflurane and fixed in a supine position on the operating table. A midline incision was made in the lower abdomen below the xiphoid process to expose the stomach wall. A line was passed under the pylorus and ligated. The solvent control group received the solvent via tail vein injection, while the drug-treated group received the drug via tail vein injection. The abdominal incision was then sutured, routine disinfection was performed, and water and food were withheld. The rats were housed individually. Eighteen hours post-surgery, the animals were sacrificed. The abdomen was opened, the esophagus was ligated near the diaphragm, the entire stomach was removed, and the contents were emptied. The stomach cavity was cut along the greater curvature, rinsed with physiological saline, and the gastric mucosa was lined with white paper and flattened. Gastric ulcers were counted and the ulcer index was scored.

[0115] 3. Group administration

[0116] Male Wistar rats were randomly divided into a solvent control group and an administration group according to their body weight. There were 25 rats in the solvent control group and 12 rats in each administration group.

[0117] 4. Experimental Evaluation Indicators

[0118] The entire stomach was removed, and the stomach cavity was cut open along the greater curvature. After rinsing with saline, the gastric mucosa was lined with white paper and flattened to count the number of gastric ulcers.

[0119] Inhibition rate (%) = (Number of ulcers in the model group - Number of ulcers in the treatment group) / Number of ulcers in the model group × 100%

[0120] 5. Experimental Results

[0121] Table 6. Effects of intravenous administration on the number of ulcers in rats with pyloric ligation-induced gastric ulcers.

[0122]

[0123] Note: Compared with the solvent control group, *P<0.05, **P<0.01, ***P<0.001, which are statistically significant.

[0124] The results showed that, compared with the solvent control group, the drug administration group significantly reduced the number of gastric ulcers in rats with pyloric ligation gastric ulcers, indicating that the powder injection of compound (I) has a significant inhibitory effect on gastric ulcers.

Claims

1. A powder injection of a compound of formula (I), comprising the active ingredient of formula (I) and an excipient, wherein, Each vial of powder for injection contains 40 mg of compound (I) and 40 mg, 125 mg, or 200 mg of excipient; the excipient is selected from mannitol; the process includes the following steps: 1) Preparation of mother liquor: first, dissolve the excipient in water for injection, then add compound (I) and dissolve it, adjust the pH value with 1 mol / L sodium hydroxide, and filter through a 0.22 μm microporous membrane; 2) Dispensing of the drug solution: dispense the above drug solution into 7 ml vials, each vial having a volume of 2.5 ml; 3) Lyophilization: place the vials in a lyophilizer and lyophilize according to the lyophilization program; 4) Stopping and capping; the pH value is 10.5~12.0; Equation (I).

2. The powder injection as described in claim 1, wherein, Each vial of powder for injection contains 125 mg of excipients.

3. The powder injection as described in claim 1, wherein, The powder injection of the compound of formula (I) also includes a chelating agent.

4. The powder injection as described in claim 3, wherein, The chelating agent is selected from sodium edetate.

5. The powder injection as described in claim 1, wherein the pH value is 11.0~12.

0.

6. Use of the powder injection as described in claim 1 in the preparation of a medicament for treating gastric ulcers.

Citation Information

Patent Citations

  • Benzimidazole derivatives and pharmaceutical compositions and uses thereof

    CN102712649A

  • Benzimidazole derivatives and pharmaceutical compositions and uses thereof

    CN102712649B

  • Enteric-coated tablet of sodium anaprazole and preparation method of enteric-coated tablet

    CN114224861A

  • Powder injection for treating peptic ulcers and preparation method thereof

    CN102038648A

  • Esomeprazole sodium sterile lyophilized powder for injection and preparation process of lyophilized powder

    CN103768028A